NuCana is winding down after failing to secure a strategic deal. A planned liquidation, cash distribution and Nasdaq delisting change the risk profile for shareholders.
NuCana is preparing to liquidate and dissolve the company after concluding that a strategic transaction was not achievable, according to a company update published on April 2, 2025, and a follow?up filing on April 15, 2025, as reported by GlobeNewswire as of 04/02/2025 and SEC filings as of 04/15/2025. The oncology drug developer plans to distribute remaining cash to shareholders, subject to approval of a liquidation and dissolution plan.
As of: 17.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: NuCana plc
- Sector/industry:…